Extract
We read with great interest the article by Dhar and coworkers [1] which, based on the data from EMBARC/Respiratory Research Network, thoroughly investigated the clinical outcomes of bronchiectasis in India. The authors have identified important predictors of poor clinical outcomes, some of which represented the critical therapeutic targets because these may represent the treatable or preventable traits. For instance, identification of the frequent exacerbators who would benefit from intensified airway clearance and macrolides therapy and pulmonary rehabilitation may result in an improved clinical outcome. Their work may also shed light on refining the management strategy for patients with bronchiectasis in many low-middle-income countries globally. In spite of these promising findings, there are some concerns that merit further discussion.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflicts of Interest: The authors declared no conflict of interest with any financial organization regarding the material discussed in the manuscript.
- Received May 21, 2022.
- Accepted November 11, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org